LeMaitre Vascular (NASDAQ:LMAT) Stock Rating Upgraded by Barrington Research

Key Points

• LeMaitre Vascular received an upgrade from Barrington Research, moving from a "market perform" rating to an "outperform" rating, with a target price of $95.00.
• The company reported $0.60 earnings per share for the last quarter, surpassing estimates and reflecting a 15.0% increase in revenue compared to the previous year.
• CEO George W. LeMaitre sold 4,399 shares, decreasing his ownership slightly while 84.64% of the stock is held by institutional investors and hedge funds.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) was upgraded by stock analysts at Barrington Research from a "market perform" rating to an "outperform" rating in a research report issued on Wednesday,Finviz reports. The brokerage presently has a $95.00 target price on the medical instruments supplier's stock. Barrington Research's price objective points to a potential upside of 10.98% from the stock's previous close.

LeMaitre Vascular Trading Up 1.5%

NASDAQ:LMAT opened at $85.60 on Wednesday. The company has a market capitalization of $1.93 billion, a P/E ratio of 43.23, a PEG ratio of 2.23 and a beta of 0.79. The company has a current ratio of 16.49, a quick ratio of 13.83 and a debt-to-equity ratio of 0.48. LeMaitre Vascular has a 12 month low of $71.42 and a 12 month high of $109.58. The firm has a fifty day simple moving average of $82.64 and a 200-day simple moving average of $86.68.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The medical instruments supplier reported $0.60 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.03. LeMaitre Vascular had a return on equity of 13.53% and a net margin of 19.96%. The business had revenue of $63.15 million for the quarter, compared to the consensus estimate of $62.48 million. During the same quarter in the previous year, the business earned $0.52 EPS. The company's quarterly revenue was up 15.0% compared to the same quarter last year. On average, equities research analysts anticipate that LeMaitre Vascular will post 1.94 earnings per share for the current year.

Insider Buying and Selling at LeMaitre Vascular

In related news, CEO George W. Lemaitre sold 4,399 shares of the business's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $85.10, for a total transaction of $374,354.90. Following the completion of the transaction, the chief executive officer directly owned 1,827,003 shares in the company, valued at $155,477,955.30. The trade was a 0.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 100,000 shares of company stock valued at $8,556,857 in the last quarter. 9.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LeMaitre Vascular

Several large investors have recently made changes to their positions in the company. Principal Financial Group Inc. raised its position in shares of LeMaitre Vascular by 3.0% in the first quarter. Principal Financial Group Inc. now owns 111,865 shares of the medical instruments supplier's stock worth $9,385,000 after acquiring an additional 3,248 shares during the period. Invesco Ltd. boosted its position in LeMaitre Vascular by 50.5% during the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after purchasing an additional 58,720 shares in the last quarter. Compass Planning Associates Inc grew its holdings in LeMaitre Vascular by 91.4% in the first quarter. Compass Planning Associates Inc now owns 11,776 shares of the medical instruments supplier's stock valued at $988,000 after purchasing an additional 5,623 shares during the period. Johnson Investment Counsel Inc. increased its position in shares of LeMaitre Vascular by 34.8% in the first quarter. Johnson Investment Counsel Inc. now owns 29,428 shares of the medical instruments supplier's stock valued at $2,469,000 after buying an additional 7,603 shares in the last quarter. Finally, Consolidated Planning Corp acquired a new position in shares of LeMaitre Vascular during the 1st quarter worth approximately $947,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.